Reports suggest that T-DXd may be effective against certain extracellular and transmembrane domain mutations, such as S310F and V659E, due to its potent bystander effect and ability to target HER2-expressing tumor cells regardless of mutation type [20, 27]. This evidence concerns the gene ERBB2 and neoplasm.